Immutep Limited - American Depositary Shares (NQ:IMMP)

4.350 UNCHANGED

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Immutep Limited - American Depositary Shares

< Previous 1 2 3 4 5 6 Next >

Why Australian Cancer Biotech Firm Immutep Stock Is Soaring On Wednesday? ↗

April 24, 2024

Immutep releases preliminary results from TACTI-003 trial showing promising outcomes for first-line treatment of HNSCC patients without PD-L1 expression. Final data expected in H1 CY2024.

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

April 24, 2024

Via Benzinga

Immutep Announces Positive Preliminary Topline Results from TACTI-003 Cohort B

April 24, 2024

From Immutep Limited

Via GlobeNewswire

Cancer Focused Immutep's Stock Soars On Tuesday - Here's Why ↗

March 05, 2024

Immutep releases promising safety and efficacy data for 90mg eftilagimod alpha combined with paclitaxel in HR+/HER2- metastatic breast cancer. No serious adverse events were reported, and a 50% overall...

Via Benzinga

Immutep Reports Promising Clinical Data from INSIGHT-003 Trial at ESMO Congress 2023

October 24, 2023

From Immutep Limited

Via GlobeNewswire

Immutep Touts Encouraging Data From Efti Triple Combination Therapy In Lung Cancer Setting ↗

May 24, 2023

Via Benzinga

Maxim Group Maintains Buy Rating for Immutep: Here's What You Need To Know ↗

May 18, 2023

Via Benzinga

Immutep Issues Development Update For Its Lead Cancer Candidate ↗

September 14, 2022

Via Benzinga

Immutep’s Efti in Combination with KEYTRUDA® Generates Excellent Overall Survival Benefit in Patients with Metastatic Non-Small Cell Lung Cancer

October 23, 2023

From Immutep Limited

Via GlobeNewswire

7 Stocks That Could Triple Your Money by 2024 ↗

August 09, 2023

If you want to get well ahead of the market and don’t mind the risk factor, check out these stocks to triple your money.

Via InvestorPlace

Benzinga's Top Ratings Upgrades, Downgrades For August 3, 2023 ↗

August 03, 2023

Via Benzinga

Why Are Immutep Shares Trading Higher? ↗

March 30, 2022

Immutep Limited (NASDAQ: IMMP) has

Via Benzinga

3 Best Penny Stocks Under $3 to Buy in June ↗

June 14, 2023

If you don’t mind the immense risks associated with high-potential opportunities, these best penny stocks under $3 could be for you.

Via InvestorPlace

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

May 24, 2023

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

May 17, 2023

Via Benzinga

Immutep Shares Spike As Cancer Tratement Shows Favorable Results In Phase 2 Trial ↗

May 17, 2023

Immutep Limited's (NASDAQ: IMMP) lead candidate — a soluble LAG-3 protein, in combination with Merck & Co Inc (NYSE: MRK) Keytruda (pembrolizumab) —

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

May 17, 2023

Via Benzinga

Immutep’s Efti in Combination with Pembrolizumab Achieves Excellent Initial Overall Survival Benefit in 1st Line Non-Small Cell Lung Cancer

May 17, 2023

From Immutep Limited

Via GlobeNewswire

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday ↗

May 17, 2023

We're starting off Wednesday with a look at the biggest pre-market stock movers traders will want to keep an eye on this morning!

Via InvestorPlace

Immutep Receives Approval to Initiate INSIGHT-005 Trial Evaluating Eftilagimod Alpha and Anti-PD-L1 Therapy BAVENCIO®

May 01, 2023

From Immutep Limited

Via GlobeNewswire

7 Best Penny Stocks Under $3 to Buy in April ↗

April 12, 2023

If you have the audacity to consider ultra-speculative opportunities, these ideas for best penny stocks under $3 might be appealing.

Via InvestorPlace

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday ↗

April 03, 2023

We're starting off the week with a breakdown of the biggest pre-market stock movers worth keeping an eye on Monday morning!

Via InvestorPlace

Why Did Immutep Ltd Stock Soar Recently?

December 28, 2022

Analysts and investors alike appear enamored with Immutep Ltd, whose earnings are growing; more of which could come from their latest product candidate.

Via MarketBeat

Topics Initial Public Offering

Immutep Enters into Second Clinical Trial Collaboration Agreement with Merck KGaA, Darmstadt, Germany, and Pfizer for New Combination Study of its First-in-Class LAG-3 Candidate, Eftilagimod Alpha, and Avelumab to Treat Urothelial Cancer

November 29, 2022

From Immutep Limited

Via GlobeNewswire

Immutep Granted New Patents in Japan and South Korea for First-in-Class LAG-3 Candidate, Eftilagimod Alpha in Chemo-Immunotherapy Combination

November 09, 2022

From Immutep Limited

Via GlobeNewswire

Why AeroClean Technologies Is Trading Higher By Over 39%; Here Are 26 Stocks Moving Premarket ↗

October 04, 2022

Gainers Bit Brother Limited (NASDAQ: BTB) rose 91.7% to $0.2150 in pre-market trading after declining around 14% on Monday.

Via Benzinga

Immutep's Lung Cancer Candidate Shows Encouraging Efficacy As Second-Line Treatment ↗

August 01, 2022

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

May 04, 2022

Via Benzinga

The Week Ahead In Biotech (May 1-7): Phathom FDA Decision, Pfizer, Vertex Pharma Lead Earnings News, Ophthalmology Conference Presentations, And More ↗

May 02, 2022

Biotech stocks posted weekly declines yet again in the week ending April 29, taking cues from the weak broader market sentiment. Big pharma earnings, clinical readouts and pipeline updates moved stocks...

Via Benzinga

The Daily Biotech Pulse: SELLA In-licenses Oncology Asset, Merck's Pneumococcal Vaccine Review Extended, Arc Biopharma COVID Drug Flunks Mid-Stage Study ↗

April 01, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours.

Via Benzinga

< Previous 1 2 3 4 5 6 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.